Six Months After Complete Capital Impairment, DXVX Has a Reason for Confidence

DXVX, whose total equity fell into negative territory in the third quarter of last year, returned to a company with a debt-to-equity ratio in the 27% range within six months.

DXVX said on the 23rd that it had signed a material transfer agreement (MTA) for its proprietary nucleic acid stabilization platform, 'KRNA,' with an Argentine pharmaceutical company specializing in vaccines. The agreement came one month after the companies first made contact at the BIO International Convention (BIO USA) held in San Diego, California, on the 22nd of last month. It is the company's fourth MTA and its first agreement with a South American company.

The counterparty's name was not disclosed under a confidentiality provision. The company will conduct formulation analysis and testing according to its own standards, and if the results are positive, the parties will move on to term-sheet and technology-transfer negotiations.

Argentina's pharmaceutical market is projected to grow from $12.3 billion in 2025 to $21.8 billion in 2034. It is considered one of the fastest-growing markets in South America.

From negative equity to 90.8 billion won

The first basis for DXVX's confidence is its financial structure. At the end of the third quarter of 2025, the company's consolidated total equity was negative 3.2 billion won. It was a time when the company was fully capital-impaired and the possibility of delisting was being discussed.

The turning point came on Dec. 30 last year. After payment was completed for a third-party allotment of new shares to the largest shareholder, total equity rose to 95.8 billion won at the end of 2025. The capital impairment was fully eliminated, with equity exceeding the 49.2 billion won in capital.

As of the end of the first quarter of 2026, total assets were 115.4 billion won and total liabilities were 24.6 billion won. Total equity was 90.8 billion won, and the debt-to-equity ratio was 27.10%. Cash and cash equivalents stood at 62.2 billion won at the same time.

During the first quarter alone, liabilities fell by 34.5 billion won, from 59.1 billion won to 24.6 billion won. The decrease resulted from a substantial portion of the proceeds from the capital increase being used to repay borrowings.

The shadow cast by the source of the funds

The money that eliminated the capital impairment was not generated by the company. Lim Jong-yoon, chairman of KORIGROUP, pledged 2,437,891 shares of HanmiScience held in his and his family's names, borrowed 100 billion won and participated in the capital increase. The loan carries an annual interest rate of 8.5% and matures in one year.

The terms of the capital increase called for the issuance of 49.21 million common shares at 2,027 won per share. The amount raised was 99.8 billion won, and the new shares are subject to a one-year lockup after listing. As a result, Chairman Lim Jong-yoon's personal ownership stake rose to 57.98%.

The planned use of the funds was 86.7 billion won for operating expenses, 8 billion won for facility investments and 5 billion won for repayment of short-term borrowings. Of the operating funds, 58 billion won is scheduled to be invested in clinical trials, preclinical studies and research and development this year. The longer clinical progress is delayed, the faster cash will be depleted.

A pipeline spread across six areas

DXVX unveiled six major pipelines at BIO USA last month. The pipelines cover oncology, metabolic disease, infectious disease, neurologic disease and ophthalmology, and CEO Kwon Gyu-chan personally delivered the presentation.

The focus is not individual drug candidates but platforms. The company is built around a room-temperature nucleic acid stabilization technology, the blood-brain barrier-penetrating peptide platform 'ACP,' and a broad-spectrum antiviral mechanism. The company says a single platform can be transferred sequentially to multiple partners across multiple indications.

CEO Kwon Gyu-chan said, "BIO USA 2026 is an opportunity to directly demonstrate the value of our technology and pipeline to global partners."

Government project and clinical data

The nucleic acid stabilization technology has also passed the government's validation process. DXVX was selected as a final Phase 2 project after completing the Phase 1 performance evaluation for the Ministry of Health and Welfare's Korean ARPA-H project.

According to simulation results presented by the company, vaccines using the technology maintained 99.9% stability for 18 months at room temperature of 25 degrees Celsius and for more than 7 years under refrigeration at 4 degrees Celsius. This contrasts with existing mRNA vaccines, which require an ultracold distribution network ranging from minus 20 degrees Celsius to minus 70 degrees Celsius. The company plans to focus through 2028 on commercialization strategy, securing intellectual property rights and developing GMP manufacturing processes.

Clinical evidence has also accumulated for the oncology pipeline. Oxford Vacmedix, a U.K. affiliate, presented Phase 1b results for its cancer vaccine 'OVM-200' at the American Society of Clinical Oncology (ASCO) meeting in May.

The study included 36 patients with advanced non-small cell lung cancer, ovarian cancer or prostate cancer. No dose-limiting toxicities or serious adverse drug reactions occurred, and injection-site reactions were limited to Grade 1. Antibody and T-cell responses were induced even in patients with Stage 4 disease; stable disease at 6 months was observed in patients with lung cancer, and a prostate-specific antigen (PSA) response was observed in patients with prostate cancer.

Professor Martin Foster said, "The observation of stable disease for 6 months in a patient with Stage 4 lung cancer is a very promising result." Oxford Vacmedix is preparing a Phase 2 combination trial with an immuno-oncology drug in Asia.

The company is also expanding its intellectual property portfolio. The patent related to the ACP platform developed by subsidiary Euvicgen, titled 'Novel Therapeutics for Neurologic Diseases and Uses Thereof,' was registered in Japan on the 16th. DXVX holds commercialization rights to the technology, which can be applied to degenerative neurologic diseases including Alzheimer disease, Huntington disease and Parkinson disease.

Deal structure put to the test

The company already has two technology-transfer deals. The agreement signed with a U.S. biotech on July 30 last year to transfer an mRNA cancer vaccine was valued at 300 billion won and included royalties of at least 10% of sales for more than 15 years after commercialization. The company said it expects sales milestones under the agreement to exceed 1.3 trillion won in the future.

However, the agreement did not include an upfront payment. Because the structure calls for payments beginning with preclinical-stage milestones, market observers have pointed out that its short-term cash-inflow effect is limited.

The second agreement had a different structure. The technology export agreement for the ACP platform signed by subsidiary Euvicgen with a U.S. biotechnology company on Aug. 18 last year was valued at 500 billion won and included an upfront payment and royalties for 10 years after launch. Blood-brain barrier-related patents were excluded from the license, leaving room for additional agreements with other companies.

The fact that neither counterparty was disclosed remains a burden. Regarding the third agreement, a company official said, "We are preparing an agreement with a well-known company and will disclose contract terms, including the upfront payment, as transparently as possible."

Core business losses remain

Separate from its financial stability, the company's earnings have not yet turned around. DXVX's consolidated revenue in 2025 was 29.4 billion won, down 13.3% from 33.9 billion won the previous year. During the same period, the company posted an operating loss of 24.3 billion won and a net loss of 29.6 billion won.

In the first quarter of 2026, the company was also found to have recorded revenue of 6.7 billion won, an operating loss of 5.3 billion won and a net loss of 6.5 billion won. The key question is how long the 99.8 billion won raised through the capital increase can cover operating losses.

The market remains cautious. The stock traded around 2,100 won on the 28th. That is less than half its 52-week high of 5,360 won, while its book value per share is 904 won.

The company had also filed no management-related disclosures under its name during the previous 30 days. All three electronic disclosures filed during that period concerned Chairman Lim Jong-yoon's holdings.